Chemiluminescence is the result of the respiratory burst generated by phagocytic cells after stimulation by antigen. The measurement of chemiluminescence represents a sensitive means for detecting antigenic stimulation and immune cell function. Although the kinetics of chemiluminescence reactions have been described, appropriate statistical methods for the evaluation of data from chemiluminescence assays have not been reported. Based on examination of data from several studies in which the chemiluminescence response of spleen cells was investigated after stimulation with the particulate antigen zymosan, recommendations are made for the design and statistical evaluation of such studies. Three parameters were used in assessing the chemiluminescence response; peak intensity of the emitted light, time to peak, and the area under the intensity-time curve. The data indicated that peak intensity alone provides an adequate characterization of the chemiluminescence response. Since percent change in response upon treatment is of interest, analysis on the log scale is appropriate, and the statistical procedure of choice in evaluating data of this type is a trend analysis. The need for a balanced allocation of treatments to avoid potential bias is demonstrated. The methods proposed are illustrated with data from two studies in which the effect of preincubation with low concentrations of ketoconazole, an antifungal agent, on the chemiluminescence response of BALB/cBY spleen cells was examined.
Normal function of phagocytic cells is critical for proper host defense against infectious agents. In particular, normal immune cell function is essential for successful defense against fungal agents of disease, since many antifungal agents are fungistatic and not fungicidal. An important activity of phagocytic cells is their ability to respond to appropriate stimuli by activation of the respiratory burst which comprises increased oxygen uptake; production of superoxide anions, hydrogen peroxide, hydroxyl radicals, and singlet oxygen; and the stimulation of the hexose monophosphate shunt. These active oxygen compounds participate in the destruction of microorganisms (1) .
In the resting state, phagocytic cells consume little oxygen. The respiratory burst begins when, in response to a suitable stimulus, an oxidase which is dormant in the resting cell is converted to an active state. This oxidase catalyzes the one-electron reduction of oxygen to superoxide anion (1, 2) . The stimulus may be a fungal or bacterial cell, a particulate antigen such as zymosan, or soluble agents such as plant lectins. This phenomenon has only been investigated extensively during the last 20 years. One result of these investigations has been the discovery that the respiratory burst is a complex metabolic series of pathways which serves to produce the highly reactive antimicrobial oxidants by the partial reduction of oxygen (1, 2) .
A sensitive way to measure the respiratory burst of phagocytic cells is based on the finding that stimulated phagocytes generate photons of light which can be detected as chemical luminescence or chemiluminescence (CL) (3, 6, 8, 9, 11, 14) . This light emission has been shown to depend both upon superoxide and myeloperoxidase-catalyzed reac-* Corresponding author.
tions and is a measure of phagocytic as well as metabolic activity in the stimulated cells (12 (14) reported that "the patterns of CL responses were reviewed for initial slopes, peaks, slopes of declining response, duration of response, and areas under the curve." We chose initially to work with three response variables; peak intensity (PEAK), time to peak (TIME), and area under the intensity-time curve (AREA). For similar data occurring in pharmacokinetics, these three parameters are important; this choice also had the virtue of practical convenience, these three quantities being among the summary information delivered by the computer. The variables peak intensity and area under the curve were evaluated on the log-transformed scale since it was felt that the percent change in these variables on treatment, as opposed to the absolute change, was of interest.
In assessing the effect on the CL response of the drug being tested, standard variance analysis techniques were used. The main focus of such an analysis is to test for the existence of systematic differences among the treatment mean responses. Consistency of treatment effects over several days of experimentation also may be investigated in the analysis of variance framework. Broadly speaking, this amounts to checking whether differences among response means remain the same from day to day, within the limits of random variation. In statistical terms this corresponds to testing for an interaction between the factors treatment and day.
Assuming that the overall analysis of variance indicates that significant differences among treatment mean responses exist, one will usually want to obtain a more detailed picture of the way in which treatment affects the response. This was done in two ways. Each dose tested was compared with the control by using the multiple comparison procedure of Dunnett (7) to account for the multiplicity of testing. In addition, since the six treatments typically corresponded to a control and five graded doses of the drug being tested, it was of interest to test for progressiveness of response with increasing concentrations of the drug. This was done by implementing the sequential test procedure of Tukey et al. (13) . A description of this procedure, written for a nonstatistical audience, may be found in Capizzi et al. (4) .
RESULTS
The general conclusions and recommendations concerning methodology reported here are based on our experience with approximately 20 studies. For purposes of exposition, results are illustrated with data from two specific experiments in which the effect of ketoconazole, an antifungal agent, on the CL response of mouse spleen cells in vitro was investigated.
Choice of response variable. In working with the three response variables PEAK, AREA, and TIME, our experience was that the first of these provided the best characterization of the CL response. This is in agreement with the findings of Welch et al. (14) . We do recommend, however, that PEAK be analyzed on the log-transformed scale, since treatment usually effected consistent changes in the magnitude of this response relative to control, rather than in the absolute size. The log-transformed variables LPEAK and LAREA were typically very highly correlated (in the studies considered, the sample correlation coefficient between the two ranged from 0.92 to 0.99) so that little extra information would be gained by analyzing LAREA as well as LPEAK.
The third variable considered, TIME, proved less useful as a characterization of the CL response. Many of the compounds assayed did not have a consistent effect on this variable from one experiment to the next: an agent which resulted in a statistically significant delay in the time to peak on one day might appear to cause an acceleration in subsequent experiments. This was explained in part by the relatively low variation in the measurement of TIME; because of this, differences in means of the order of a minute were often declared statistically significant. It is not clear, however, that such differences should be considered of practical importance, particularly in view of the fact that the starting time of a run is well-defined only to within about 30 s. Thus, TIME to peak intensity may not be a meaningful parameter for assessing the effect of treatment on the CL response.
Analysis of variance. The results of an analysis of variance performed on data from two studies investigating the effect of ketoconazole on the CL response of mouse spleen cells are listed in Table 1 . In these studies, treatments corresponded to a control (preincubation with DMSO alone) and five concentrations of ketoconazole (0.08, 0.16, 0.31, 0.63, and 1.25 pug/ml) in DMSO. Experimentation was carried out over 2 days, with six experimental assays being performed on each day. Different batches of spleen cells were used on both days. Results for these two studies were representative of our experience with data of this nature and provide a useful frame of reference in illustrating the general issues that arise. Inspection of the analysis of variance table reveals a number of interesting features.
The treatment by day interaction was negligible for these data (P = 0.823). This was reassuring, since a significant interaction would mean that treatment had a different effect on the variable LPEAK on the experimentation of the 2 days. The fact that this interaction was not significant, (neither in these, nor the other studies considered) indicates that the effect of the antifungal agent tested was consistent bThe F value is the ratio of the variation attributable to the effect (as measured by the mean square) to the variation due to error (error mean square). A large value of the F statistic is evidence that the factor has a significant effect. ' The P value is for testing the hypothesis that the given factor has no effect on response. The smaller the P value, the stronger the evidence that the factor does indeed have an effect. In particular, if the P value is less than 0.05, the effect is said to be statistically significant at the usual (5%) level. 
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" The response variable used is PEAK, the peak intensity of emitted light. To put the differences among measurement channel means in perspective, note that a 6% drop in means would be declared statistically significant at the 5% level (based on the observed variability and 12 runs per channel mean). The variation among channel means is thus quite sizeable.
b Backtransformed from the log scale. Numbers represent counts per minute. over time and over the different cell batches used in the experimentation.
The amount of variation in response from assay to assay, as measured by the mean square for assay in Table 1 , was considerable. This was not too surprising, since the average background response for assays later in the day tended to be systematically lower than for early assays. Similar remarks apply to channel-to-channel variability. This is measured by the mean square for channel in Table 1 ; the size of this quantity indicates that there was considerable systematic variation among the mean responses observed for the six channels of the Biolumat. Table 2 (response means by channel) shows the nature of this systematic effect. The numbers presented there are reasonably typical of our experience in these studies: on average, channel 1 always gave considerably higher readings than did channel 5 or channel 6, no matter what compound was being tested.
Evaluation of treatment effects. The absence of a treatment by day interaction indicated that it was reasonable to summarize the effect of the test compound by presenting the average response pooled over the experiments from both days for each dose level (Table 3) . For the ketoconazole data, the overall F test for differences among treatment means gave a P value of 0.13. The interpretation is that there was some, though not overwhelming, evidence for differences among the treatment means. Since the F test is nonspecific in nature and, thus, not very sensitive, more directed tests, which take the specific nature of the treat- 
DISCUSSION
The results of the analyses indicate a number of general points worth noting. (i) The lack of a treatment by day interaction indicates a consistent effect of treatment over time and over the different cell batches used in experimentation. This reproducibility of treatment effects was evident when peak intensity was assessed on the log scale. The implication is that a particular treatment resulted in a fairly consistent percent change in response. While the background response level did not vary much for the 2 days of experimentation reported here, in general, the use of different cell batches resulted in quite disparate levels of background response. In this situation, percent change rather than absolute change in response is the pertinent measure of the effect of treatment. Accordingly, analysis on the log scale is appropriate. (ii) The considerable systematic variation in response from assay to assay and from channel to channel made it imperative to use a design in these studies in which the allocation of treatments was balanced across assays and across channels. That is, whenever possible, each treatment should appear the same number of times on each assay and in each channel. In our experimental framework of six treatments and six assays per day, a Latin square design provided a convenient means of achieving this balance; other balanced or partially balanced designs are possible and may be more convenient in different experimental settings. The use of a balanced design has two advantages. First, it allows the systematic assay-to-assay and channelto-channel variability to be subtracted out of the residual (error) variation in the analysis. This is important, since the test for treatment differences essentially compares the variation among treatment mean responses to the residual, or random, variation. Failure to subtract out existing systematic variation would result in severe overestimation of the amount of random noise in the data, thereby making any treatment effects harder to detect. Thus, a balanced design allows a more sensitive test for treatment differences. The second advantage of balance is that it helps to avoid bias in the results. Given the magnitude of the observed systematic channel and assay effects, failure to implement a balanced design in these experiments would have serious consequences for the valid estimation of treatment effects. For example, if a single treatment were consistently assigned to the same measurement channel of the Biolumat, any observed lowering in the response could not be attributed solely to the effect of that treatment; the possibility of it being due to that particular channel yielding consistently lower readings could not be discounted. Similarly, running all replicates of a particular treatment in the same experimental assay would be inadvisable; to do so would confuse the effect of that treatment with the systematic assay effect. Balancing over assays and channels helps to avoid such bias, as well as enhancing precision, when assessing treatment effects. (iii) The fact that the trend analysis gave a significant result for the ketoconazole data, while the Dunnett test did not, reflects the greater sensitivity of the trend test. This increased sensitivity is a quite general phenomenon (4, 10, 13) and stems from the fact that the trend test addresses a more specific question than does the Dunnett procedure, and the trend test uses the data in a more directed and sensitive way to answer that question. In situations in which several doses of a drug are being tested, we strongly recommend that a trend analysis be performed, as it is a more powerful means of addressing the question of interest. For instance, the significant negative trend observed in the ketoconazole data indicates that, whereas comparison of each of the individual concentrations tested in these experiments with control were not statistically significant, testing at higher concentrations might well result in a more dramatic, and significant, inhibition of the CL response. Subsequent experiments with higher concentrations of ketoconazole have demonstrated that this was indeed the case (Abruzzo et al., submitted).
In conclusion, if a reduction in the CL response is to be used as an indicator of possible inhibition of the immune response, then the use of a statistically sound experimental design, as well as an appropriate analysis of the resulting data, is an absolute necessity. We believe that the methods proposed here provide a useful approach to the design and evaluation of studies to investigate the CL response.
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